Merck Archives - Vista Partners LLC | HomeVista Partners LLC

New York’s First Severe Mpox Case Arrives – And So Does a New Chapter for Preparedness -( $GOVX $IBB $XBI )

by John F. Heerdink, Jr. 2 days ago 89Views 0Likes

New York City woke up this week to a headline it doesn’t particularly enjoy: its first documented case of severe mpox, specifically the clade I strain associated with more serious disease and higher mortality. Health officials confirmed that the patient had recently…

Alpha Therapy’s Radiopharma Unicorn Surge -( $AZN $BMY $NVS $IBB $XBI )

by John F. Heerdink, Jr. March 13, 2026 206Views 0Likes

Biotech innovators are pioneering RNA‑optimized fusions for targeted alpha therapies (TATs), positioning themselves as first‑movers in the broader radiopharma market that is exploding with demand for precision cancer killers. Radiopharma Market Momentum Builds Billions The radiopharma sector, blending alpha‑particle precision with smart…

The Billion-Dollar Hangover of Falling Vaccination Rates And Why GeoVax Brought the Coffee -( $GOVX $IBB $XBI )

by John F. Heerdink, Jr. March 9, 2026 168Views 0Likes

GeoVax Labs (NASDAQ: GOVX) sits at the intersection of a public health problem and a balance-sheet opportunity: falling vaccination rates are quietly inflating a future bill that taxpayers, hospitals and employers will all be forced to pay. As policymakers tally the hidden…

Ivonescimab vs Keytruda: The High‑Stakes HARMONi‑3 Interim That Could Flip the Script for Summit Therapeutics -( $MRK $SMMT $IBB $XBI )

by John F. Heerdink, Jr. February 24, 2026 257Views 0Likes

Summit Therapeutics’ (SMMT) latest tweak to its clinical playbook has turned what was already one of biotech’s higher‑stakes stories into something closer to appointment viewing for Wall Street. A Phase 3 Trial Adds a Plot Twist Summit now plans an interim progression‑free…

GeoVax Expands Gedeptin Strategy: Riding Merck’s Keytruda Wave in a $200 Billion IO Market -( $GOVX $MRK $IBB $XBI )

by John F. Heerdink, Jr. February 18, 2026 365Views 0Likes

GeoVax’s (NASDAQ: GOVX) latest move to lock down combination rights for its Gedeptin cancer platform reads less like a routine licensing notice and more like an oncology strategy upgrade—complete with optionality, IP leverage, and a quietly ambitious grab for front-line real estate…

Inside Biopharma’s 2025 Deal Wave: Record Licensing, Big Pharma M&A and a Frozen IPO Market -( $JPM $IBB $XBI $LLY $MRK $NVS $PFE )

by John F. Heerdink, Jr. January 21, 2026 212Views 0Likes

Biopharma spent 2025 behaving like a sector that has finally read the fine print on the cost of capital—and decided to let someone else pick up the bar tab. Licensing and M&A stepped into the role IPOs used to play, and did…

GeoVax Brings Its Differentiated Biotech Platform to Center Stage at J.P. Morgan Healthcare Week – Jan. 12-15 – ( $GOVX $MRK $IBB $XBI #JPM2026 )

by Vista Partners LLC January 6, 2026 131Views 0Likes

GeoVax Labs (NASDAQ: GOVX) is heading into the 44th Annual J.P. Morgan Healthcare Conference week ("JPM2026") in San Francisco, CA Jan. 12-15 with the kind of narrative biotech investors typically like to hear: a differentiated platform, large funded trials lining up, and…

Radiopharmaceutical Gold Rush: Why Wall Street Is Finally Paying Attention to Nuclear Medicine -( $BMY $NVS $TLX )

by Vista Partners LLC December 23, 2025 511Views 0Likes

Radiopharmaceuticals are quietly becoming the part of oncology that no longer sits in the hospital basement—capital, M&A desks, and regulators have all joined the tour. For investors, the space now looks less like a scientific hobby and more like a pipeline strategy…

Merck Mixes Up Its Pipeline With Cidara $9.2B Acquisition—GeoVax Keeps Driving Towards Value in the Vaccine Lane -( $MRK $CDTX $GOVX $IBB )

by Vista Partners LLC November 15, 2025 417Views 0Likes

Merck (MRK), ever the discerning giant of Big Pharma, has decided to join the prophylactic party by acquiring Cidara Therapeutics (CDTX) for a headline-grabbing $9.2 billion—a move that whispers both “strategic pipeline expansion” and “Keytruda’s patent clock is ticking, folks.” In a…

U.S. Based GeoVax Labs Seeks To Challenge Bavarian Nordic’s Vaccine Monopoly Amid $3 Billion Buyout – ( $GOVX $BVNKF $IBB $XBI )

by John F. Heerdink, Jr. September 22, 2025 317Views 0Likes

GeoVax Labs, Inc. (NASDAQ: GOVX), an American clinical-stage biotechnology company, is advancing its Modified Vaccinia Ankara (MVA) vaccine platform, positioning itself as a key domestic alternative to Europe's Bavarian Nordic in addressing critical global health threats such as Mpox and smallpox. This…

Merck

Your Guide To Staying Informed In The Markets